Sign inJoin waitlistJoin the waitlist

Amir Jazaeri

Associate Professor, Gynecologic Oncology & Reproductive Medicine · University of Texas M D Anderson Cancer Center

Credentials: · · · · ·

History

University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present
University of Virginia Medical Center
Present

National Cancer Institute & The University of Texas
2002–2004
National Cancer Institute
2000–2002
Obstetrics and Gynecology
University of Virginia Medical Center
1996–2000
University of Virginia School of Medicine
1992–1996

Research

Breast cancer classification and prognosis based on gene expression profiles from a population-based study
Proceedings of the National Academy of Sciences of the United States of America · 2003 · 1,471 citations
Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance
Nature Medicine · 2023 · 383 citations
Selective loss of estrogen receptor beta in malignant human colon
Cancer Research · 2000 · 272 citations

Shannon Westin
32 papers
Anil Sood
24 papers
Karen Lu
22 papers · 1 as a fellow
Jeffrey How
18 papers · 18 as a fellow
Pamela Soliman
17 papers
Nicole Fleming
15 papers
Emily Hinchcliff
13 papers · 8 as a fellow
LR
Laurel Rice
13 papers
Michael Frumovitz
12 papers
Aaron Shafer
11 papers
Larissa Meyer
10 papers
Aung Naing
9 papers

Grants

Development of the MasSpec Pen Technology to Guide Surgical Decisions in the Care for Patients with Ovarian Cancer
National Cancer Institute · R01
PI · $1.4M · Baylor College of Medicine
2025–2030
General Clinical Research Center
National Center for Research Resources · M01
Project lead · $15.5K · University of Virginia
2008–2009

Clinical trials

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2023–2027
Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100
Principal investigator · Recruiting · Phase 1, Phase 2
M.D. Anderson Cancer Center
2023–2027
Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer
Principal investigator · Suspended · Phase 1, Phase 2
M.D. Anderson Cancer Center
2023–2028
Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix
Principal investigator · Active not recruiting · Phase 2
M.D. Anderson Cancer Center
2022–2027